Results 11 to 20 of about 137,833 (211)
Primary Non-Hodgkin Lymphoma of The Cervix [PDF]
International Journal of Hematology-Oncology and Stem Cell Research, 2011 Background: There are only a few reports that exist regarding primary non-Hodgkin lymphoma of the genital tract. In this article, one case of primary B-cell type non-Hodgkin lymphoma (NHL) of the cervix is presented.
Haleh Ayatollahi +2 more
doaj +2 more sources
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers [PDF]
, 2012 Background: Increased glycolytic activity is a hallmark of cancer, allowing staging and restaging with 18F-fluorodeoxyglucose-positron-emission-tomography (PET).
Agostinelli, Claudio +9 more
core +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources
Association of group erythrocyte antigens and B-cell non-Hodgkin lymphoma
Regulatory Mechanisms in Biosystems, 2016 We analyzed the frequency distribution of blood groups AB0, Rhesus and Kell in patients with B-cell non-Hodgkin lymphoma. An increase of D− patients (31.0%) among ill in comparison to healthy individuals (16.5%) was found.
U. V. Tymoshenko +4 more
doaj +1 more source
Brazilian Journal of Otorhinolaryngology, 2021 Introduction: The diagnostic approach to patients with isolated asymptomatic cervical lymphadenopathy varies between excisional biopsy and follow-up. When the anamnesis, physical examination, laboratory and imaging findings are not sufficient to identify
Mehmet Erkan Kaplama +2 more
doaj +1 more source
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper [PDF]
, 2016 Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian ...
Barosi, Giovanni +7 more
core +1 more source
BMJ, 2018 The term non-Hodgkin lymphoma (NHL) covers a spectrum of malignant disorders arising from cells of the immune system and manifesting predominantly as lymphadenopathy or solid tumour. The classification of NHL is complex and ever-evolving, with more than 50 different subtypes listed in the latest WHO classification of lymphoma (1).
Bowzyk Al-Naeeb, Anna +3 more
openaire +3 more sources
BMC Oral Health, 2022 Background Little is known about the epidemiology of lymphomas occurring in oral and para-oral sites, especially in developing countries such as Egypt.
Madiha Ashoub +5 more
doaj +1 more source
Qualitative results from a phase II pilot randomised controlled trial of a lymphoma nurse-led model of survivorship care [PDF]
, 2018 Purpose: To explore and describe lymphoma survivors’ thoughts and perceptions of the components of a nurse led lymphoma survivorship clinic intervention. Methods: An exploratory, qualitative descriptive study using interviews from 10 participants who had
Bulsara, Caroline +2 more
core +2 more sources
Primary mediastinal lymphoma: diagnosis and treatment options. [PDF]
, 2014 Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a
DI ROCCO, Alice +4 more
core +1 more source